PFA
TCRT icon

Pathway Financial Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Pathway Financial Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-207
Closed -$38K – 138
2022
Q2 		$38K Buy
207
+7
+4% +$669 0.02% 130
2022
Q1 		$20K Buy
200
+7
+4% +$898 0.01% 141
2021
Q4 		$31K Buy
+193
New +$42.4K 0.01% 135

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pathway Financial Advisors's TCRT Position: Q3 2022 in Review

Pathway Financial Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 207 shares — an estimated $38K sold.

Pathway Financial Advisors first reported a position in TCRT in Q4 2021 and held it in 3 quarters. The position peaked at $38K in Q2 2022. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

  • Pathway Financial Advisors reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Pathway Financial Advisors sold 207 Alaunos Therapeutics shares in Q3 2022, an estimated $38K.
  • Pathway Financial Advisors first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 3 quarters.
  • Pathway Financial Advisors's Alaunos Therapeutics position peaked at $38K in Q2 2022.
  • 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on Pathway Financial Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.